- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT06937476
Нейробиологические механизмы патологического размышления и эффектов арипипразола
Исследование нейробиологических механизмов, лежащих в основе патологического размышления и фармакологических эффектов арипипразола
This randomized, single-blind (assessor-blind) controlled trial aims to investigate the efficacy of aripiprazole as an augmentation strategy for treating pathological rumination in patients with major depressive disorder (MDD). Pathological rumination-defined as repetitive, intrusive, and uncontrollable negative thinking-has been identified as a major transdiagnostic risk factor for the development, maintenance, and recurrence of depression. Even during clinical remission, ruminative symptoms often persist and strongly predict relapse.
Previous clinical observations and experimental studies suggest that aripiprazole, a partial dopamine D2 receptor agonist, can significantly improve cognitive symptoms and reduce rumination in MDD patients when added to selective serotonin reuptake inhibitors (SSRIs). However, rigorous randomized controlled trials (RCTs) directly targeting rumination and validating this effect remain limited.
In this study, patients with acute MDD episodes and high levels of rumination will be randomly assigned to receive either escitalopram monotherapy (20 mg/day) or escitalopram (20 mg/day) plus low-dose aripiprazole (2.5-5 mg/day) for 8 weeks. Clinical assessments will be repeated during the 8-week treatment phase, including interim monitoring visits for efficacy and safety. The primary clinical endpoint is the change in Ruminative Responses Scale (RRS) scores from baseline to week 8.The assignment will remain blinded to outcome assessors and data analysts, while patients and treating clinicians will remain unblinded due to dose titration and safety monitoring requirements.
Participants will undergo [18F]fallypride-PET-MRI scanning at baseline and again at week 10, following discontinuation of aripiprazole at the end of week 8 (with no aripiprazole administered during weeks 9-10), to measure striatal dopamine D2 receptor binding and explore its association with changes in rumination symptoms and treatment efficacy.
The primary outcome is the change in Ruminative Responses Scale (RRS) scores. Secondary outcomes include changes in depressive symptoms and dopamine D2 receptor availability. This trial will provide neurobiological insights into the dopaminergic mechanisms underlying pathological rumination and explore the therapeutic potential of D2 receptor modulation in this cognitive domain.
Обзор исследования
Статус
Вмешательство/лечение
Подробное описание
Revised Detailed Description(Single-Blind Assessor-Blind Version)
Background:
Pathological rumination is characterized by repetitive, intrusive, and difficult-to-control negative thinking that often persists even after depressive symptoms remit. It has been recognized as a proximal risk factor for the onset, maintenance, and recurrence of major depressive disorder (MDD). Recent meta-analyses and longitudinal studies have confirmed that rumination significantly contributes to poor treatment outcomes and is associated with trait-like persistence across diagnostic and symptomatic states.
Rationale:
Aripiprazole, a partial dopamine D2 receptor agonist, has shown potential in augmenting antidepressant therapy by improving cognitive control and reducing rumination. Clinical observations have suggested that adjunctive aripiprazole can significantly alleviate ruminative symptoms in MDD patients, yet high-quality randomized controlled trials (RCTs) directly targeting rumination as a primary outcome remain lacking. Dopaminergic dysfunction-particularly altered D2 receptor availability in the striatum-may underlie the neurobiological mechanisms of pathological rumination. Therefore, combining pharmacological intervention with molecular neuroimaging offers a promising translational approach to validate therapeutic targets.
Study Design:
This study adopts a randomized, single-blind (assessor-blind) controlled trial design. Eligible participants include unmedicated or drug-naive MDD patients with high levels of rumination and healthy controls. Patients with pathological rumination will be randomly assigned to one of two intervention arms:
Group I: Escitalopram (20 mg/day) + aripiprazole (2.5-5 mg/day) Group II: Escitalopram monotherapy (20 mg/day)
The aripiprazole dose will be titrated from 2.5 mg/day to a maximum of 5 mg/day based on tolerability. During weeks 9-10, aripiprazole will not be administered (having been discontinued at the end of week 8), with escitalopram maintained. No additional psychotropic medications are allowed. Clinical assessments will be performed repeatedly during the 8-week treatment phase, including interim monitoring visits for efficacy and safety, with the primary clinical endpoint assessed at week 8. Outcome assessors and data analysts will remain blinded to treatment allocation to minimize assessment bias.
Neuroimaging Assessment:
Participants will undergo two [18F]fallypride-PET-MRI scans (at baseline and at week 10, following discontinuation of aripiprazole at the end of week 8). Additional clinical symptom scales will be obtained at week 10, concurrent with post-washout PET-MRI, to characterize symptom status and clinical change at the time of neuroimaging.
The scanning protocol includes:
Intravenous injection of 5 mCi [18F]-fallypride Dynamic PET acquisition in three blocks (70 min, 50 min, 60 min) with resting intervals Image reconstruction of binding potential (BPND) maps using simplified reference tissue modeling (SRTM), with the cerebellum as the reference region
Outcome Measures:
Primary outcome: Change in Ruminative Responses Scale (RRS) score from baseline to week 8; Secondary outcomes: Changes in depressive symptoms (e.g., HAMD), striatal D2 receptor BPND values, and the correlations between imaging changes and clinical improvement
Hypothesis:
Aberrant striatal dopamine D2 receptor availability is a neurobiological substrate of pathological rumination. Modulating D2 receptor activity via aripiprazole can reduce rumination and enhance treatment response. Neuroimaging markers are expected to correlate with symptom improvement, providing mechanistic insight into the dopaminergic contributions to depressive cognition.
Тип исследования
Регистрация (Действительный)
Фаза
- Непригодный
Контакты и местонахождение
Места учебы
-
-
Hunan
-
Changsha, Hunan, Китай, 410011
- The Second Xiangya Hospital of Central South University
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
For Patients With Major Depressive Disorder (MDD):
- Age 18 to 45 years
- Any sex
- Self-identified Han Chinese
- Right-handed
- Education level of junior high school or above
- Able to understand the informed consent form and complete self-report assessments
- Meets DSM-5 diagnostic criteria for Major Depressive Disorder (MDD) based on the Structured Clinical Interview for DSM-5 (SCID)
- Currently experiencing a major depressive episode
- 24-item Hamilton Depression Rating Scale (HAMD-24) score >= 21 at screening/baseline
- Young Mania Rating Scale (YMRS) score <= 5 at screening/baseline
- No psychotropic medication use, other than benzodiazepines, within 6 weeks before baseline
Pathological Rumination Group:
- Must meet all of the following criteria:
- Subjective experience of persistent and difficult-to-control ruminative thinking
- Interview-confirmed pathological rumination characterized by all of the following features:
- Repetitive
- Intrusive
- Difficult to disengage from
- Unproductive
- Occupying substantial mental resources
- Ruminative Responses Scale (RRS) score >= 61
Low Rumination Group:
- Does not meet criteria for the Pathological Rumination Group
- Ruminative Responses Scale (RRS) score < 61
For Healthy Controls:
- Age 18 to 45 years
- Any sex
- Self-identified Han Chinese
- Right-handed
- Education level of junior high school or above
- Able to understand the informed consent form and complete self-report assessments
- Does not meet DSM-5 diagnostic criteria for any current or past psychiatric disorder based on the Structured Clinical Interview for DSM-5 (SCID)
- 24-item Hamilton Depression Rating Scale (HAMD-24) score < 8 at screening/baseline
- Young Mania Rating Scale (YMRS) score <= 5 at screening/baseline
- No psychotropic medication use within 6 weeks before baseline
Exclusion Criteria:
For Patients With Major Depressive Disorder (MDD):
- Meets DSM-5 diagnostic criteria for any psychiatric disorder other than anxiety disorders
- Major depressive disorder with psychotic features
- Severe suicidal ideation or suicidal behavior
- History of traumatic brain injury or loss of consciousness
- Serious neurological or medical illness that, in the judgment of the investigators, may affect study participation or data interpretation, including but not limited to thyroid disorders, lupus, diabetes, active infection, or major trauma
- Cardiac pacemaker or any metallic implant incompatible with MRI or PET
- History of alcohol or substance dependence
- Pregnant or breastfeeding
- Personal history of epilepsy or family history of epilepsy in a first-degree relative
- Receipt of non-pharmacological psychiatric interventions within the past 6 months, including electroconvulsive therapy (ECT), repetitive transcranial magnetic stimulation (rTMS), or structured psychotherapy
For Healthy Controls:
- Meets DSM-5 diagnostic criteria for any current or past psychiatric disorder
- First-degree relative with a history of major psychiatric disorder
- Severe suicidal ideation or suicidal behavior
- History of traumatic brain injury or loss of consciousness
- Serious neurological or medical illness that, in the judgment of the investigators, may affect study participation or data interpretation, including but not limited to thyroid disorders, lupus, diabetes, active infection, or major trauma
- Cardiac pacemaker or any metallic implant incompatible with MRI or PET
- History of alcohol or substance dependence
- Pregnant or breastfeeding
- Personal history of epilepsy or family history of epilepsy in a first-degree relative
- Receipt of electroconvulsive therapy (ECT), repetitive transcranial magnetic stimulation (rTMS), or structured psychotherapy within the past 6 months
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Одинокий
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Escitalopram Only - MDD with Pathological Rumination
Patients diagnosed with major depressive disorder (MDD) and exhibiting pathological rumination will receive escitalopram monotherapy at 20 mg/day for 8 weeks. |
Escitalopram will be administered orally at a fixed dose of 20 mg/day for 8 weeks. This SSRI antidepressant is used as baseline pharmacological treatment for patients with major depressive disorder (MDD), either as monotherapy or in combination with aripiprazole. No other psychotropic medications are allowed during the study period. |
|
Экспериментальный: Escitalopram + Aripiprazole - MDD with Pathological Rumination
Patients with MDD and pathological rumination will receive escitalopram (20 mg/day) and low-dose aripiprazole (2.5-5 mg/day) for 8 weeks, with titration based on tolerability. |
Escitalopram will be administered orally at a fixed dose of 20 mg/day for 8 weeks. This SSRI antidepressant is used as baseline pharmacological treatment for patients with major depressive disorder (MDD), either as monotherapy or in combination with aripiprazole. No other psychotropic medications are allowed during the study period. Aripiprazole will be administered as an adjunctive treatment to escitalopram at an initial dose of 2.5 mg/day, titrated up to 5 mg/day based on tolerability. Treatment will last 8 weeks, with aripiprazole discontinued at the end of week 8. This intervention aims to evaluate the efficacy of dopaminergic augmentation in reducing pathological rumination symptoms. |
|
Без вмешательства: MDD with Low Rumination - Observational
MDD patients with low levels of rumination (RRS < 61) will receive no pharmacological intervention and serve as a naturalistic observation group. |
|
|
Без вмешательства: Healthy Controls
Healthy individuals with no psychiatric history will serve as non-clinical imaging and behavioral controls. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Change in Ruminative Responses Scale (RRS) score from baseline to week 8
Временное ограничение: Baseline and week 8
|
The 22-item Ruminative Responses Scale (RRS) will be used to assess the severity of pathological rumination. The primary outcome is the change in total RRS score from baseline to the end of the 8-week treatment period. Total scores range from 22 to 88, with higher scores indicate more severe rumination. |
Baseline and week 8
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Change in 24-item Hamilton Depression Rating Scale (HAMD-24) score
Временное ограничение: Baseline and week 8
|
Depression severity will be assessed using the 24-item HAMD. The outcome is the change in total score from baseline to week 8. This will help evaluate overall clinical improvement in depressive symptoms. |
Baseline and week 8
|
Другие показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Change From Baseline to Week 10 in Striatal Dopamine D2/3 Receptor Binding Potential Measured by [18F]Fallypride PET
Временное ограничение: Baseline and week 10
|
The outcome measure is the change from baseline to week 10 in prespecified striatal [18F]fallypride positron emission tomography (PET) binding potential relative to non-displaceable uptake (BPND), reflecting dopamine D2/3 receptor availability in prespecified striatal regions of interest. Follow-up PET imaging will be performed at week 10 following discontinuation of adjunctive aripiprazole at the end of week 8 (with no adjunctive aripiprazole administered during weeks 9 to 10). |
Baseline and week 10
|
|
Change From Baseline to Week 10 in Prefrontal Cortex Dopamine D2/3 Receptor Binding Potential Measured by [18F]Fallypride PET
Временное ограничение: Baseline and week 10
|
The outcome measure is the change from baseline to week 10 in [18F]fallypride positron emission tomography (PET) binding potential relative to non-displaceable uptake (BPND), reflecting dopamine D2/3 receptor availability in a prespecified prefrontal cortex region of interest. Follow-up PET imaging will be performed at week 10 following discontinuation of adjunctive aripiprazole at the end of week 8 (with no adjunctive aripiprazole administered during weeks 9 to 10). |
Baseline and week 10
|
|
Change From Baseline to Week 10 in Prespecified Functional Connectivity Measured by Resting-State Functional Magnetic Resonance Imaging
Временное ограничение: Baseline and week 10
|
The outcome measure is the change from baseline to week 10 in a prespecified resting-state functional magnetic resonance imaging (fMRI) functional connectivity metric derived from a predefined region of interest or network of interest. Follow-up MRI will be performed at week 10 concurrent with post-washout PET-MRI following discontinuation of adjunctive aripiprazole at the end of week 8 (with no adjunctive aripiprazole administered during weeks 9 to 10). |
Baseline and week 10
|
|
Change From Baseline to Week 10 in Prespecified Neurite Density Index Measured by Diffusion MRI
Временное ограничение: Baseline to Week 10
|
The outcome measure is the change from baseline to week 10 in a prespecified neurite density index derived from diffusion magnetic resonance imaging using neurite orientation dispersion and density imaging (NODDI) in a predefined region of interest. Follow-up MRI will be performed at week 10 concurrent with post-washout PET-MRI following discontinuation of adjunctive aripiprazole at the end of week 8 (with no adjunctive aripiprazole administered during weeks 9 to 10). |
Baseline to Week 10
|
|
Change From Baseline to Week 10 in Prespecified Neuromelanin-Sensitive Magnetic Resonance Imaging Signal in a Substantia Nigra Region of Interest
Временное ограничение: Baseline and week 10
|
The outcome measure is the change from baseline to week 10 in a prespecified neuromelanin-sensitive magnetic resonance imaging (NM-MRI) signal metric derived from a predefined substantia nigra region of interest. The specific metric will be defined according to the prespecified imaging analysis plan. Follow-up MRI will be performed at week 10 concurrent with post-washout PET-MRI following discontinuation of adjunctive aripiprazole at the end of week 8 (with no adjunctive aripiprazole administered during weeks 9 to 10). |
Baseline and week 10
|
|
Change From Baseline to Week 8 in Neurocognitive Composite Score
Временное ограничение: Baseline and week 8
|
Neurocognition will be assessed using a standardized neurocognitive test battery. The outcome measure is the change in the prespecified neurocognitive composite score from baseline to week 8. Higher scores indicate better neurocognitive performance. |
Baseline and week 8
|
|
Change From Baseline to Week 8 in Serum High-Sensitivity C-Reactive Protein Concentration
Временное ограничение: Baseline and week 8
|
The outcome measure is the change in serum high-sensitivity C-reactive protein (hs-CRP) concentration from baseline to week 8 as an exploratory peripheral inflammatory biomarker. |
Baseline and week 8
|
|
Change From Baseline to Week 8 in Serum Brain-Derived Neurotrophic Factor Concentration
Временное ограничение: Baseline and week 8
|
The outcome measure is the change in serum brain-derived neurotrophic factor (BDNF) concentration from baseline to week 8 as an exploratory neurotrophic biomarker. |
Baseline and week 8
|
|
Change From Baseline to Week 8 in Serum Cortisol Concentration
Временное ограничение: Baseline and week 8
|
The outcome measure is the change in serum cortisol concentration from baseline to week 8 as an exploratory neuroendocrine biomarker. |
Baseline and week 8
|
|
Change From Baseline to Week 8 in Prespecified Urinary Metabolomic Metric
Временное ограничение: Baseline and week 8
|
The outcome measure is the change in a prespecified urinary metabolomic metric from baseline to week 8 as an exploratory biomarker of metabolic change. The specific metric will be defined according to the prespecified metabolomics analysis plan. |
Baseline and week 8
|
|
Change From Baseline to Week 8 in Gut Microbiome Shannon Diversity Index
Временное ограничение: Baseline and week 8
|
The outcome measure is the change in gut microbiome Shannon diversity index from baseline to week 8 as an exploratory stool-based microbiome biomarker. |
Baseline and week 8
|
|
Change From Baseline to Week 8 in Montgomery-Åsberg Depression Rating Scale Total Score
Временное ограничение: Baseline and week 8
|
The Montgomery-Åsberg Depression Rating Scale (MADRS) is a clinician-rated measure of depressive symptom severity. The outcome measure is the change in total MADRS score from baseline to week 8. Total scores range from 0 to 60, with higher scores indicating more severe depressive symptoms. |
Baseline and week 8
|
|
Change From Baseline to Week 8 in Hamilton Anxiety Rating Scale Total Score
Временное ограничение: Baseline and week 8
|
The Hamilton Anxiety Rating Scale (HAM-A) is a clinician-rated measure of anxiety symptom severity. The outcome measure is the change in total HAM-A score from baseline to week 8. Total scores range from 0 to 56, with higher scores indicating more severe anxiety symptoms. |
Baseline and week 8
|
|
Change From Baseline to Week 8 in Perceived Deficits Questionnaire-Depression Total Score
Временное ограничение: Baseline and week 8
|
The Perceived Deficits Questionnaire-Depression (PDQ-D) is a patient-reported measure of subjective cognitive dysfunction in depression. The outcome measure is the change in total PDQ-D score from baseline to week 8. Total scores range from 0 to 80, with higher scores indicating more severe subjective cognitive difficulties. |
Baseline and week 8
|
Соавторы и исследователи
Спонсор
Соавторы
Следователи
- Главный следователь: Yan Zhang, Second Xiangya Hospital of Central South University
Публикации и полезные ссылки
Общие публикации
- van der Velden AM, Scholl J, Elmholdt EM, Fjorback LO, Harmer CJ, Lazar SW, O'Toole MS, Smallwood J, Roepstorff A, Kuyken W. Mindfulness Training Changes Brain Dynamics During Depressive Rumination: A Randomized Controlled Trial. Biol Psychiatry. 2023 Feb 1;93(3):233-242. doi: 10.1016/j.biopsych.2022.06.038. Epub 2022 Jul 22.
- Song AK, Hay KR, Trujillo P, Aumann M, Stark AJ, Yan Y, Kang H, Donahue MJ, Zald DH, Claassen DO. Amphetamine-induced dopamine release and impulsivity in Parkinson's disease. Brain. 2022 Oct 21;145(10):3488-3499. doi: 10.1093/brain/awab487.
- Wang Y, Lu Z, Xun G. Effect of aripiprazole on promoting cognitive function and enhancing clinical efficacy in patients with first-episode depression on escitalopram: A randomized controlled trial. J Affect Disord. 2024 Jan 1;344:159-168. doi: 10.1016/j.jad.2023.10.038. Epub 2023 Oct 10.
- Ehring T. Thinking too much: rumination and psychopathology. World Psychiatry. 2021 Oct;20(3):441-442. doi: 10.1002/wps.20910. No abstract available.
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Действительный)
Завершение исследования (Действительный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
- Неврологические проявления
- Заболевания нервной системы
- Психические расстройства
- Заболевания пищеварительной системы
- Желудочно-кишечные заболевания
- Расстройства настроения
- Кормление и расстройства пищевого поведения
- Депрессивное расстройство
- Патологические состояния, признаки и симптомы
- Признаки и симптомы
- Синдром руминации
- Депрессивное расстройство, майор
- Нейроповеденческие проявления
- Органические химические вещества
- Гетероциклические соединения, 1-кольцо
- Гетероциклические соединения
- Гетероциклические соединения, 2-кольцо
- Гетероциклические соединения, слитое кольцо
- Амины
- Нитрилы
- Хинолоны
- Хинолины
- Пропиламины
- Пиперазины
- Бензофураны
- Арипипразол
- Эсциталопрам
Другие идентификационные номера исследования
- LYG20230074
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
Individual participant data (IPD) that underlie the published results (including de-identified clinical and imaging data) will be available upon reasonable request from qualified researchers. Data will be shared after publication, with prior approval from the corresponding author and ethical oversight. Supporting documents such as the study protocol and statistical analysis plan will also be made available where applicable.
Сроки обмена IPD
Individual participant data (IPD) and supporting documents will be available beginning 6 months after publication of the main results and will remain available for up to 5 years, or as long as the dataset is maintained by the research team.
Критерии совместного доступа к IPD
De-identified clinical and imaging data will be made available to qualified researchers with a methodologically sound proposal, subject to approval by the principal investigator and institutional ethics board. Data requests can be submitted by email and will require signing a data use agreement.
Совместное использование IPD Поддерживающий тип информации
- STUDY_PROTOCOL
- САП
- МКФ
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .